Not logged in In Vivo Validation ofPAPSS1(3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target Leung, Ada W. Y.; Veinotte, Chansey J.; Melong, Nicole; Oh, Min Hee; Chen, Kent; Enfield, Katey S. S.; Backstrom, Ian; Warburton, Corinna; Yapp, Donald; Berman, Jason N.; Bally, Marcel B.; Lockwood, William W. Share Save
Share Save
Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267 Kalra, Jessica; Anantha, Malathi; Warburton, Corinna; Waterhouse, Dawn; Yan, Hong; Yang, Young-Joo; Strut, Dita; Osooly, Maryam; Masin, Dana; Bally, Marcel B. Share Save
QLT0267, a small molecule inhibitor targeting integrin-linked kinase ( ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model Kalra, Jessica; Warburton, Corinna; Fang, Karen; Edwards, Lincoln; Daynard, Tim; Waterhouse, Dawn; Dragowska, Wieslawa; Sutherland, Brent W.; Dedhar, Shoukat; Gelmon, Karen; Bally, Marcel Share Save
Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs Chiu, Gigi N. C.; Edwards, Lincoln A.; Kapanen, Anita I.; Malinen, Melina M.; Dragowska, Wieslawa H.; Warburton, Corinna; Chikh, Ghania G.; Fang, Karen Y. Y.; Tan, Sophia; Sy, Jonathan; Tucker, Catherine; Waterhouse, Dawn N.; Klasa, Richard; Bally, Marcel B. Share Save
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway:: Therapeutic implications for combination therapy with rapamycin Dragowska, Wieslawa H.; Verreault, MaiTe; Yapp, Donald T. T.; Warburton, Corinna; Edwards, Lincoln; Ramsay, Euan C.; Huxham, Lynsey A.; Minchinton, Andrew I.; Gelmon, Karen; Bally, Marcel B. Share Save
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839):: Drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction Warburton, C; Dragowska, WH; Gelmon, K; Chia, S; Yan, H; Masin, D; Denyssevych, T; Wallis, AE; Bally, MB Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
CLINICAL CANCER RESEARCH.png)
.png){kind=icon}
Share.png){kind=icon}
Save